Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Granisetron Transdermal System for Prevention of Cisplatin Chemoradiotherapy-Induced Nausea and Vomiting in Head and Neck Cancer
2018-003669-32Phase 2Terminated
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of granisetron in head and neck cancer (HNC) and Upper Respiratory Tract Neoplasm, sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoint: Complete control of nausea and vomiting during chemoradiation. Started Oct 2020; status: terminated.
02
Drugs
granisetron
03
Conditions
head and neck cancer (HNC)Upper Respiratory Tract Neoplasm
Beyond the preview
Go deeper on 2018-003669-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003669-32.